These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 11219309

  • 1. Update on cross-resistance of fluoroquinolones.
    Garau J.
    Int J Clin Pract Suppl; 2000 Dec; (115):94-8. PubMed ID: 11219309
    [No Abstract] [Full Text] [Related]

  • 2. [Where are quinolones going? New agents in development].
    Holzgrabe U.
    Pharm Unserer Zeit; 2001 Dec; 30(5):446-8. PubMed ID: 11575182
    [No Abstract] [Full Text] [Related]

  • 3. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
    Roychoudhury S, Catrenich CE, McIntosh EJ, McKeever HD, Makin KM, Koenigs PM, Ledoussal B.
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
    [Abstract] [Full Text] [Related]

  • 4. [Mechanism of action and resistance to fluoroquinolones].
    Alarcón T, López-Brea M.
    Enferm Infecc Microbiol Clin; 1996 Feb; 14(2):111-7. PubMed ID: 8714159
    [No Abstract] [Full Text] [Related]

  • 5. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection.
    Ruiz J.
    J Antimicrob Chemother; 2003 May; 51(5):1109-17. PubMed ID: 12697644
    [Abstract] [Full Text] [Related]

  • 6. Fluoroquinolone resistance: mechanisms and epidemiology.
    Tillotson GS, Dorrian I, Blondeau J.
    J Med Microbiol; 1997 Jun; 46(6):457-61. PubMed ID: 9379475
    [No Abstract] [Full Text] [Related]

  • 7. Effectiveness of fluoroquinolones against gram-positive bacteria.
    Bush K, Goldschmidt R.
    Curr Opin Investig Drugs; 2000 Sep; 1(1):22-30. PubMed ID: 11249591
    [Abstract] [Full Text] [Related]

  • 8. [Quinolones. Gyrase inhibitors].
    Höffler D.
    Internist (Berl); 1994 May; 35(5):484-9. PubMed ID: 8021119
    [No Abstract] [Full Text] [Related]

  • 9. [New quinolones, current therapies].
    Auckenthaler R.
    Schweiz Rundsch Med Prax; 1988 Nov 08; 77(45):1217-8. PubMed ID: 2847274
    [No Abstract] [Full Text] [Related]

  • 10. Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance.
    Schmitz FJ, Higgins PG, Mayer S, Fluit AC, Dalhoff A.
    Eur J Clin Microbiol Infect Dis; 2002 Sep 08; 21(9):647-59. PubMed ID: 12373497
    [Abstract] [Full Text] [Related]

  • 11. Mode of action of new quinolones: the inhibitory activity on DNA gyrase.
    Sato K, Hoshino K, Mitsuhashi S.
    Prog Drug Res; 1992 Sep 08; 38():121-32. PubMed ID: 1319080
    [No Abstract] [Full Text] [Related]

  • 12. Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
    Inagaki H, Takahashi H, Takemura M.
    Bioorg Med Chem Lett; 2004 Oct 18; 14(20):5193-8. PubMed ID: 15380226
    [Abstract] [Full Text] [Related]

  • 13. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
    Rolston KV, Yadegarynia D, Kontoyiannis DP, Raad II, Ho DH.
    Int J Infect Dis; 2006 May 18; 10(3):223-30. PubMed ID: 16439177
    [Abstract] [Full Text] [Related]

  • 14. Molecular mechanisms of drug inhibition of DNA gyrase.
    Lewis RJ, Tsai FT, Wigley DB.
    Bioessays; 1996 Aug 18; 18(8):661-71. PubMed ID: 8760340
    [Abstract] [Full Text] [Related]

  • 15. [Recent development in quinolone compounds antitumor quinolones].
    Yang YS, Zhao SR, Ji RY, Chen KX.
    Yao Xue Xue Bao; 1998 Aug 18; 33(2):157-60. PubMed ID: 11938953
    [No Abstract] [Full Text] [Related]

  • 16. Mechanisms of quinolone action and microbial response.
    Hawkey PM.
    J Antimicrob Chemother; 2003 May 18; 51 Suppl 1():29-35. PubMed ID: 12702701
    [Abstract] [Full Text] [Related]

  • 17. [How are quinolones used in clinical practice? Gyrase antagonists from the viewpoint of the hospital pharmacist].
    Schurz JK.
    Pharm Unserer Zeit; 2001 May 18; 30(5):400-5. PubMed ID: 11575176
    [No Abstract] [Full Text] [Related]

  • 18. [Mechanisms of pandrug-resistance of Pseudomonas aeruginosa].
    Shen JL, Zhu DM, Wang MG.
    Zhonghua Yi Xue Za Zhi; 2008 Jul 08; 88(26):1859-62. PubMed ID: 19040025
    [Abstract] [Full Text] [Related]

  • 19. [Mechanisms of bacterial resistance to quinolones].
    Taléns-Visconti R, Garrigues TM, Cantón E.
    Rev Esp Quimioter; 2002 Mar 08; 15(1):25-31. PubMed ID: 12582434
    [Abstract] [Full Text] [Related]

  • 20. Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis.
    Cholongitas E, Papatheodoridis GV, Lahanas A, Xanthaki A, Kontou-Kastellanou C, Archimandritis AJ.
    Liver Int; 2005 Feb 08; 25(1):57-61. PubMed ID: 15698399
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.